RPRX
Royalty Pharma plc - Class A
PE ratio, current and historical analysis
- Stocks
- Healthcare
- NASDAQ: RPRX
- PE Ratio
The price-to-earnings ratio for Royalty Pharma plc - Class A stock stands at 32.61 as of Aug 21, 2026. This is based on the current EPS of $1.88 and the stock price of $61.31 per share. An increase of 35% has been recorded in the PE ratio compared to the average of 24.1 of the last four quarters.
RPRX PE ratio history
Over the last six years, the average PE ratio of Royalty Pharma plc - Class A has been 43.24. The current 32.61 P/E ratio is 25% lower than the historical average. In the past six years, RPRX's PE ratio peaked in the Dec 2022 quarter at 395.2, with a price of $39.52 and an EPS of $0.1. The Sep 2024 quarter marked the lowest point at 11.01, with a price of $28.29 and an EPS of $2.57.
Royalty Pharma plc - Class A PE ratio by year
Maximum annual increase: 1,377.94% in 2022
Maximum annual decrease: -97.2% in 2023
| Year | PE ratio | PE change | Price | EPS |
|---|---|---|---|---|
| 2025 | 21.59 | 62.45% | $38.64 | $1.79 |
| 2024 | 13.29 | 20.16% | $25.51 | $1.92 |
| 2023 | 11.06 | -97.2% | $28.09 | $2.54 |
| 2022 | 395.2 | 1,377.94% | $39.52 | $0.1 |
| 2021 | 26.74 | -29.48% | $39.85 | $1.49 |
| 2020 | 37.92 | N/A | $50.05 | $1.32 |
| 2019 | N/A | N/A | N/A | N/A |
| 2018 | N/A | N/A | N/A | N/A |
| 2017 | N/A | N/A | N/A | N/A |
Royalty Pharma plc - Class A PE ratio by quarter (TTM)
| Year | PE ratio | PE change | Price | EPS |
|---|---|---|---|---|
| Jun 2026 | 29.82 | 19.38% | $56.07 | $1.88 |
| Mar 2026 | 24.98 | 15.7% | $47.97 | $1.92 |
| Dec 2025 | 21.59 | 8.33% | $38.64 | $1.79 |
| Sep 2025 | 19.93 | 28.33% | $35.28 | $1.77 |
| Jun 2025 | 15.53 | 23.25% | $36.03 | $2.32 |
| Mar 2025 | 12.6 | -5.19% | $31.13 | $2.47 |
| Dec 2024 | 13.29 | 20.71% | $25.51 | $1.92 |
| Sep 2024 | 11.01 | -36.94% | $28.29 | $2.57 |
| Jun 2024 | 17.46 | 2.89% | $26.37 | $1.51 |
| Mar 2024 | 16.97 | 53.44% | $30.37 | $1.79 |
| Dec 2023 | 11.06 | -84.11% | $28.09 | $2.54 |
| Sep 2023 | 69.59 | 24.51% | $27.14 | $0.39 |
| Jun 2023 | 55.89 | 14.79% | $30.74 | $0.55 |
| Mar 2023 | 48.69 | -87.68% | $36.03 | $0.74 |
| Dec 2022 | 395.2 | 1,021.13% | $39.52 | $0.1 |
RPRX Price vs fair value
RPRX average PE ratio chart
What this chart measures
The Historical Valuation Regime chart shows where the stock's current valuation sits relative to its own historical valuation range over the selected lookback period.
This is a history-relative tool, not a market-relative percentile. It does not compare the stock to other companies. Instead, it compares each historical valuation reading to the stock's own past readings.
Percentile logic
The threshold lines are calculated them from the stock's real historical values using percentile interpolation. That is why some colored bands are narrow while others are wide: the band widths reflect how the stock actually traded through time.
Regime map
| Historical percentile | Regime | Chart meaning |
|---|---|---|
| 0-10 | Historically Low | Deep cheap zone |
| >10-25 | Below Average | Cheap relative to history |
| >25-75 | Average | Within the normal historical range |
| >75-90 | Above Average | Expensive relative to history |
| >90-100 | Historically High | Extreme or stretched valuation |
How to read each part
| Chart element | What it tells you |
|---|---|
| Main line | The actual historical valuation values over time for the selected metric. |
| Dashed horizontal lines | The stock's computed P10, P25, Median, P75, and P90 thresholds for the selected period. |
| Colored bands | The historical valuation zones between those thresholds. |
| Metric boxes | Current ratio, historical median, current percentile, and current regime. |
| Timeline strip | A condensed regime history showing how the stock moved between cheap, fair, and expensive states across each observation. |
Important metric definitions
Current Percentile is the percentile rank of the latest valid historical observation within the selected lookback range.
Current Regime is assigned directly from the latest observation's percentile bucket using the fixed 10 / 25 / 75 / 90 cutoffs shown above.
How to use it well
This chart is most useful for answering a narrow question: Is this stock trading high, low, or normal relative to its own history? It works best alongside growth, profitability, and forward-looking business analysis, because a stock can deserve a higher or lower regime if its business quality has changed.
Currently, RPRX's PE ratio is higher than its 3-year historical average, but it is lower than the 5-year average.
PE comparison
With a P/E of 32.61, RPRX stands above the Healthcare sector and the industry average. In comparison with its Healthcare sector average of 24.52, Royalty Pharma plc - Class A's P/E is 33% higher.
RPRX PE vs peers
Frequently asked questions
What is Royalty Pharma plc - Class A's PE ratio?
The price to earnings ratio for RPRX stock as of Aug 21, 2026, stands at 32.61.
What is the 3-year average PE ratio for Royalty Pharma plc - Class A (RPRX)?
The 3-year average price to earnings ratio for RPRX stock is 21.99.
What is the 5-year average PE ratio for Royalty Pharma plc - Class A (RPRX)?
The 5-year average price to earnings ratio for RPRX stock is 45.55.
What is the highest PE ratio for RPRX?
The highest quarterly PE ratio in the last six years has been 395.2 and it was in the Dec 2022 quarter.
How does the current PE ratio for RPRX compare to its historical average?
RPRX's current price to earnings ratio is 25% below its 6-year historical average.
How is RPRX's PE ratio calculated (Royalty Pharma plc - Class A PE ratio formula)?
The P/E ratio is obtained by dividing the latest price of a stock by its trailing twelve months EPS. As of today (Aug 21, 2026), Royalty Pharma plc - Class A's stock price is $61.31. The earnings per share for the trailing twelve months (TTM) ending Jun 2026 is $1.88. Therefore, Royalty Pharma plc - Class A's PE ratio for today is 32.61. PE RATIO(32.61) = STOCK PRICE($61.31) / TTM EPS($1.88)
All PE ratio stats are based on quarterly TTM periods, unless otherwise specified.